The first-ever double-blind, randomized clinical trial for fungal mycetoma, underway in Sudan, had enrolled 84 patients by January 2019, the threshold for interim analysis. The primary objective of the study is to demonstrate the superiority of fosravuconazole over the current standard, itraconazole.
15-17 February 2019
- DNDi – co-sponsoring the event and presentation on the open innovation project MycetOS
- Monique Wasuna, Director DNDi Africa – chair for a session on international collaboration for mycetoma
- Nathalie Strub-Wourgaft, NTD Director – session on the way forward for mycetoma
67th Annual Meeting
28 October – 1 November 2018
New Orleans, USA
- Nathalie Strub-Wourgaft, NTD Director – presentation on fexinidazole in a symposium on sleeping sickness elimination
- Colin Forsyth, Chagas Epidemiologist, Sergio Sosa Estani, Head of Chagas Clinical Programme, Eric Chatelain, Head of Drug Discovery Programme – symposium on screening and diagnosis of Chagas disease
- Poster and oral presentations on sleeping sickness, visceral leishmaniasis, Chagas, onchocerciasis, and mycetoma
Former DNDi Medical Director Dr Nathalie Strub-Wourgaft takes over leadership of NTD programme
DNDi is pleased to announce the appointment of Dr Nathalie Strub-Wourgaft as the new Director of Neglected Tropical Diseases. She will assume her new role as NTD Director and member of DNDi’s Executive Team as of 1 July 2018.
3-4 October 2018
- DNDi – sessions on the LEAP Platform activities, policy, the AfriKADIA project, PKDL, and capacity strengthening
by Lim W, Melse Y, Konings M, Phat Duong H, Eadie K, Laleu B, Perry B, Todd M, Ioset J-R, and van de Sande W.
PLOS Neglected Tropical Diseases, April 2018
30 June-4 July 2018
Amsterdam, the Netherlands
Ed Zijlstra, Senior Consultant, DNDi – session on mycetoma
Drug Discovery News [14 March 2018]
“Working the crowd”
Global Health NOW [1 March 2018]
“The road ahead for the most neglected disease”
Africa Science Gateway [15 February 2018]
“DNDi and partners in new platform to defeat mycetoma”
Global Health NOW [8 February 2018]
“An open pharma approach targets a terrible disease”
IP Watch [7 February 2018]
“New open source drug discovery initiative takes aim at ‘devastating’ disease”
Science & Entreprise [7 February 2018]
“Open-source discovery seeks neglected disease drug”
Computerworld [7 February 2018]
“Researchers look to open source to tackle deadly infection”
Geneva, Rotterdam, Sydney – 6 February 2018
The MycetOS (Mycetoma Open Source) project was launched today by the University of Sydney, Erasmus MC, and DNDi to use an Open Pharma approach to discover compounds that could lead to new treatments for patients suffering from fungal mycetoma (eumycetoma), a devastating disease for which current treatments are ineffective, expensive, and toxic.
The Lancet Global Health Blog [12 January 2018]
“Visualizing an alternative biomedical R&D system”
December 8, 2017
DNDi presented at the event on the NTD Drug Discovery Booster, Chagas disease, and mycetoma.
A l’occasion de l’Evénement économique 2017 du 9 novembre dernier, la Chambre de commerce, d’industrie et des services de Genève (CCIG), le Département de la sécurité et de l’économie (DSE) et l’Office de Promotion des Industries et des Technologies (OPI) ont décerné le Prix 2017 de l’innovation à l’initiative Médicaments contre les Maladies Négligées (DNDi).
As part of the ‘Evénement économique 2017’ that took place on November 9, the Geneva Chamber of Commerce, Industry and Services (CCIG), the Department of Security and Economy (DSE) and the Office for the Promotion of Industries and Technologies (OPI) awarded the Innovation Prize 2017 to the Drugs for Neglected Diseases initiative (DNDi).